Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity

Rhea-AI Summary

Hemogenyx Pharmaceuticals (LSE:HEMO) has announced the exercise of warrants for 67,371 new ordinary shares. The warrants, originally granted on March 11, 2025, have generated subscription monies of £235,799 for the company.

The Warrant Shares will be admitted to trading on the LSE's main market on September 10, 2025. Following admission and including the previously announced 250,000 new ordinary shares, the company's total issued shares and voting rights will increase to 5,361,267.

Positive

• Receipt of £235,799 in subscription monies from warrant exercise
• Successful warrant conversion indicates investor confidence
• Expansion of total shares to 5,361,267 enhances market liquidity

Negative

• Potential dilution of existing shareholders' ownership

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

LONDON, UK / ACCESS Newswire / September 5, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that it has received notices to exercise warrants over 67,371 new ordinary shares in the Company (the "Warrant Shares").

The Warrant Shares are being issued pursuant to the exercise of warrants granted and announced on 11 March 2025. Subscription monies of £235,799 have been received by the Company in respect of the exercise.

Admission and Total Voting Rights

Application will be made for the Warrant Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 10 September 2025 ("Admission").

Upon Admission (and including the 250,000 new ordinary shares being issued as announced on 3 September 2025), the total number of issued shares and the total number of voting rights in the Company will be 5,361,267.

The above figure of 5,361,267 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company will keep the market informed of future developments as trials proceed.

Enquiries:

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City .

The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on ACCESS Newswire

FAQ

How many warrants were exercised in Hemogenyx Pharmaceuticals' September 2025 announcement?

Hemogenyx announced the exercise of warrants for 67,371 new ordinary shares, which were originally granted on March 11, 2025.

What is the total amount of subscription money received by Hemogenyx from the warrant exercise?

The company received £235,799 in subscription monies from the warrant exercise.

When will the new Warrant Shares begin trading on the LSE?

The Warrant Shares are expected to begin trading on the LSE's main market at 8:00 a.m. on September 10, 2025.

What will be Hemogenyx's total number of issued shares after the warrant exercise?

Following the admission of both the warrant shares and the previously announced 250,000 new ordinary shares, the total number of issued shares will be 5,361,267.